证券代码：002923 证券简称：润都股份 公告编号：2025-035 珠海润都制药股份有限公司 关于硫酸氨基葡萄糖氯化钠复盐 登记号：Y20230001261 通知书编号：2025YS00693 一、药品基本情况 原料药名称：硫酸氨基葡萄糖氯化钠复盐 申请人：珠海润都制药股份有限公司 申请事项：境内生产化学原料药上市申请 受理号：CYHS2460151 获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的关于硫酸氨基葡萄糖氯化钠复盐（以下简称："本品"）《化学原料 药上市申请批准通知书》。现将有关情况公告如下： 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 葡萄糖氯化钠复盐境内生产化学原料药上市申请注册申报资料并获受理，2024年 资料，2025年08月获得《化学原料药上市申请批准通知书》。 二、对公司的影响及风险提示 本品适用于治疗原发性及继发性骨关节 ...

Group 1: Resumption of Trading - Jin Chengzi plans to acquire 55% stake in Samit and will resume trading tomorrow; Samit specializes in high-precision fast-reflecting mirror business [1] - Quzhou Development intends to purchase 95.4559% of Xian Dao Electronics and will resume trading tomorrow; Xian Dao focuses on the R&D of sputtering targets and evaporation materials for vacuum coating [1] Group 2: Mergers, Acquisitions, and Capital Increases - China Shipbuilding's dissenting shareholders' acquisition request price is set at 30.02 yuan per share [2] - Jiangsu Suopu plans to raise no more than 1.5 billion yuan through a private placement for the ethylene acetate and EVA integration project (Phase I) [3] - Guangli Microelectronics is acquiring 100% of LUCEDA NV to strategically position itself in silicon photonics technology [4] Group 3: Share Buybacks, Increases, and Equity Transfers - Zhenlei Technology has raised its share buyback price from 38.13 yuan per share to 74 yuan per share [5] - Fuanna has conducted its first buyback of 1 million shares [6] - Shaanxi Jinye plans to repurchase shares worth between 40 million and 70 million yuan, with loans not exceeding 63 million yuan [7] - Donghua Energy's controlling shareholder's concerted action party has received a commitment letter for a special loan to increase holdings, not exceeding 225 million yuan [8] - Taimusi's controlling shareholder intends to transfer 29.99% of the company's shares, with Guangzhou State-owned Assets Supervision and Administration Commission becoming the actual controller [9] Group 4: External Investments and Daily Operations - Haikang obtained the clinical trial approval notice for the innovative drug HSK47977 tablets [10] - Rundou Co., Ltd. received approval for the listing application of glucosamine sulfate sodium chloride compound as a chemical raw material drug [11] - Beilu Pharmaceutical's subsidiary Haichang Pharmaceutical's iodine mepivacaine chemical raw material drug has been approved for listing [12] - Baiyun Airport signed a cooperation contract with China Duty Free Group for the operation of the T3 terminal's outbound duty-free project [13] - Guoshield Quantum plans to sign a sales contract worth 76.5418 million yuan with China Telecom Quantum Group for the sale of quantum key distribution hardware and software [14] Group 5: Performance Changes - Zhenlei Technology's net profit for the first half of 2025 is 62.3197 million yuan, a year-on-year increase of 1006.99%; the company continues to strengthen its advantages in special fields such as data links, electronic countermeasures, wireless communication terminals, next-generation radios, and phased array communications, achieving significant growth in orders and projects [15] - Jingchen Co., Ltd. reported a net profit of 497 million yuan for the first half of the year, a year-on-year increase of 37.12% [16] - China Unicom's net profit for the first half of 2025 is 6.349 billion yuan, a year-on-year increase of 5.1% [17] - Shuanghui Development's net profit for the first half of the year is 2.323 billion yuan, a year-on-year increase of 1.17%; the company plans to distribute 6.5 yuan per 10 shares [18] - Jinlongyu's net profit for the first half of the year is 1.756 billion yuan, a year-on-year increase of 60.07% [19]

智通财经APP讯，润都股份(002923.SZ)发布公告，公司近日收到国家药品监督管理局签发的关于硫酸氨 基葡萄糖氯化钠复盐(以下简称："本品")《化学原料药上市申请批准通知书》。本品适用于治疗原发性 及继发性骨关节炎。本品获批进一步丰富了公司产品品类，有利于提升公司的市场竞争力，对公司的未 来经营业绩产生积极影响。 ...

Group 1 - The core point of the article is that Rundu Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Glucosamine Sulfate Sodium Chloride Compound, which is indicated for the treatment of primary and secondary osteoarthritis [1] Group 2 - The approved drug is specifically aimed at treating osteoarthritis, a common joint condition that affects many individuals [1]

Core Viewpoint - Rundu Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of glucosamine sulfate sodium chloride compound, which is intended for the treatment of primary and secondary osteoarthritis, enhancing the company's product portfolio and market competitiveness, positively impacting future operational performance [1] Company Summary - The approved drug will enrich the company's product categories, which is beneficial for improving market competitiveness [1] - The approval is expected to have a positive effect on the company's future operating performance [1] Industry Summary - The market sales of the newly approved drug may be influenced by various uncertain factors, including policy environment and market changes [1]

格隆汇8月12日丨润都股份(002923.SZ)公布，公司近日收到国家药品监督管理局签发的关于硫酸氨基葡 萄糖氯化钠复盐(以下简称："本品")《化学原料药上市申请批准通知书》。本品适用于治疗原发性及继 发性骨关节炎。 ...